[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356290-105":59,"doc-detail-356290-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biomarkers-of-response-to-neoadjuvant-palbociclib-plus-anastrozole-in-endocrine-resistant-estrogen-receptor-positiveher2-negative-breast-cancer-a-phase-2-trial","Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial","","CDK4/6 inhibitors improve outcomes for estrogen receptor (ER) positive/HER2-negative breast cancer, but intrinsic and acquired resistance limits benefit. In the NeoPalAna Endocrine-Resistant cohort, 34 patients with clinical stage II/III ER+/HER2– disease resistant to standard neoadjuvant endocrine therapy received neoadjuvant palbociclib plus anastrozole with serial biopsies. Complete cell cycle arrest at cycle 1 day 15 was achieved in 57.6%. Resistance correlated with higher tumor grade, Ki67, and PAM50 subtypes, with reduced ER signaling and activation of cell cycle, mTOR, interferon, JAK/STAT, and immune checkpoint pathways. A 33-gene signature predicting Ki67 response also showed prognostic value in a metastatic validation cohort, supporting dysregulated pathways as resistance mechanisms and biomarkers of CDK4/6 inhibitor response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarkers-of-response-to-neoadjuvant-palbociclib-plus-anastrozole-in-endocrine-resistant-estrogen-receptor-positiveher2-negative-breast-cancer-a-phase-2-trial/356290/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarkers-of-response-to-neoadjuvant-palbociclib-plus-anastrozole-in-endocrine-resistant-estrogen-receptor-positiveher2-negative-breast-cancer-a-phase-2-trial/356290.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment was evaluated in the NeoPalAna Endocrine-Resistant cohort?","Question",{"text":112,"@type":113},"Patients received neoadjuvant palbociclib plus anastrozole (ANA/PAL), with serial biopsies analyzed for response biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the primary endpoint and how often was it achieved?",{"text":117,"@type":113},"The primary endpoint was complete cell cycle arrest (CCCA) defined by Ki67C1D15 ≤ 2.7%. It was achieved in 57.6% of evaluable patients.",{"name":119,"@type":110,"acceptedAnswer":120},"Which factors were associated with resistance to ANA/PAL?",{"text":121,"@type":113},"ANA/PAL resistance (Ki67C1D15 > 10%) was linked to higher pre-treatment tumor grade and Ki67, along with specific PAM50 subtypes and reduced ER signaling with upregulation of multiple signaling and immune checkpoint pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356290,1790176951,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Article [https://doi.org/10.1038/s41467-026-68570-6](https://doi.org/10.1038/s41467-026-68570-6)  \nBiomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrineresistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial  \nReceived: 17 October 2024  \n\n| Accepted: 7 January 2026 |\n| --- |\n| |\n| Check for updates |\n\nTim Kong 1,2,3,4, Alex Mabry 1,2, Maureen Highkin1, Anthony Z. Wang5, Jeremy Hoog1, Zhanfang Guo1, Adrian Gonzales-Gonzales1, Shana Thomas1, Yingduo Song 1, Feng Gao6, Mateusz Opyrchal 1, Lindsay Peterson1,  \nFoluso Ademuyiwa 1, Julie Margenthaler7, Rebecca Aft7,  \nKatherine Glover-Collins7, Leslie Nehring1, Yu Tao6, Souzan Sanati8,  \nIan S. Hagemann 8, Fouad Boulos8, Matthew Holt9, Li Ding 1, Wenge Zhu 10, Stephen T. Oh 3,8,11, Jianxin Wang 12, Agnieszka K. Witkiewicz12,13,  \nErik S. Knudsen 12, Ron Bose 1, Jason D. Weber 1, Matthew Goetz14, Donald Northfelt15, Jingqin Luo 6,16  & Cynthia X. Ma 1,16   \nCDK4/6 inhibitors (CDK4/6i) improve outcomes for estrogen receptor (ER) positive/HER2-negative breast cancers (BCs), yet intrinsic and acquired resistance exist. Here, we evaluated anastrozole in combination with palbociclib (ANA/PAL) in the NeoPalAna Endocrine-Resistant cohort (NCT01723774). Thirty-four patients with clinical stage II/III ER + /HER2– BCs resistant to standard neoadjuvant endocrine therapy (on-treatment Ki67 > 10%) received neoadjuvant ANA/PAL, with serial biopsies analyzed. The primary endpoint, complete cell cycle arrest (CCCA; Ki67C1D15 ≤ 2.7% at cycle 1, day 15), was achieved in 57.6% of patients (95%CI: 39.2–74.5%). Resistance to ANA/PAL (Ki67C1D15 > 10%) was associated with higher pre-treatment tumor grade, Ki67, and speciﬁc PAM50 subtypes. Resistant tumors demonstrated reduced ER signaling and upregulation of cell cycle, mTOR, interferon, JAK/STAT, and immune checkpoints. Additionally, a 33-gene signature that predicted neoadjuvant Ki67 response to ANA/PAL was prognostic in a metastatic validation cohort. Theseﬁndings underscore dysregulatedoncogenic pathways as potential resistance mechanisms and biomarkers of response to CDK4/6i.  \nA major challenge in treating ER+/HER2 − breast cancer (BC) is endocrine resistance1. The discovery of cyclin D/CDK4/6-Rb as the major effector of ER signaling and endocrine resistance mechanisms2–6 led to the development of CDK4/6 inhibitors (CDK4/ 6is)7. These agents block Rb phosphorylation, which hinders E2F transcription factors from activating the expression of genes  \nrequired for G1 to S phase transition8. Three CDK4/6is are FDA approved and have revolutionized the treatment for ER + BC9,10. However, despite their impressive anti-tumor activity, intrinsic and acquired resistance exist. There is a critical unmet need to understand the underlying mechanisms of resistance and developing response biomarkers9,10.  \nA full list of afﬁliations appears at the end of the paper. [e-mail:](e-mail: jingqinluo@wustl.edu)[ jingqinluo@wustl.edu](e-mail: jingqinluo@wustl.edu); [cynthiaxma@wustl.edu](cynthiaxma@wustl.edu)  \nThe NeoPalAna trial (NCT01723774) is a multi-cohort single-arm phase 2 neoadjuvant study of the CDK4/6i palbociclib (PAL) plus anastrozole (ANA) in clinical stage II/III ER+/HER2 − BC, aimed at assessing the antiproliferative effect of PAL in primary BC and discovering response biomarkers. We have previously reported the results of the initial cohorts (NeoPalAna Initial), including the PIK3CA mutated and the PIK3CA wild-type cohorts11. We observed a potent antiproliferative effect of PAL across a broad range of clinicopathologic and mutation proﬁles, including BCs resistant to ANA monotherapy. Few patients (6 of 50 patients) did not achieve CCCA (Ki67C1D15 ≤ 2.7%) . Analysis of these resistant cases suggested an association with high-risk PAM50 types and persistent E2F-target gene expression11.  \nTo further investigate PAL resistance mechanisms in endocrine therapy (ET)-resistant BC, we opened the Endocrine-Resistan","cbCaiqhXR2ClDtYN","https://ap.wps.com/l/cbCaiqhXR2ClDtYN","pdf",4703934,17,"English","# Results\n## Patient characteristics\n## Safety and clinical responses\n## Primary endpoint and Ki67 response","[{\"question\":\"What treatment was evaluated in the NeoPalAna Endocrine-Resistant cohort?\",\"answer\":\"Patients received neoadjuvant palbociclib plus anastrozole (ANA/PAL), with serial biopsies analyzed for response biomarkers.\"},{\"question\":\"What was the primary endpoint and how often was it achieved?\",\"answer\":\"The primary endpoint was complete cell cycle arrest (CCCA) defined by Ki67C1D15 ≤ 2.7%. It was achieved in 57.6% of evaluable patients.\"},{\"question\":\"Which factors were associated with resistance to ANA/PAL?\",\"answer\":\"ANA/PAL resistance (Ki67C1D15 \\u003e 10%) was linked to higher pre-treatment tumor grade and Ki67, along with specific PAM50 subtypes and reduced ER signaling with upregulation of multiple signaling and immune checkpoint pathways.\"}]","Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial | PDF",1790124449,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23fc1d29302a64c10134c66f6de4e4a3.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93b194f37466adbf4ba87dfb5c5c4952.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/565aba9ae331ab912255b3dbd01cc959.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/859629b0d89e8f3ed225c05c74882ff9.webp",980,1301]